Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Gilead Sciences (NASDAQ:GILD) had its target price boosted by Royal Bank Of Canada from $98.00 to $100.00 in a note issued to investors on Wednesday,MarketScreener reports. The firm currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective would indicate a potential downside of 14.34% from the company’s current price.

Other research analysts also recently issued reports about the company. UBS Group lifted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a report on Friday, July 25th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Finally, Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.08.

Gilead Sciences Stock Down 1.3%

Shares of GILD opened at $116.74 on Wednesday. The company has a market capitalization of $144.85 billion, a PE ratio of 23.26, a PEG ratio of 0.80 and a beta of 0.34. Gilead Sciences has a 12 month low of $84.17 and a 12 month high of $121.83. The stock’s 50-day moving average price is $114.57 and its two-hundred day moving average price is $110.19. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,402,130 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently modified their holdings of GILD. Norges Bank purchased a new stake in shares of Gilead Sciences in the second quarter worth approximately $2,150,268,000. Price T Rowe Associates Inc. MD raised its stake in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new position in shares of Gilead Sciences in the first quarter valued at approximately $620,415,000. Ameriprise Financial Inc. grew its holdings in shares of Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after acquiring an additional 5,392,191 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.